The authors conclude that KRAS mutation status can be used to identify the subgroup of patients with irinotecan-refractory metastatic CRC who are most likely to respond to cetuximab.

KRAS G12D and G12V mutations in pancreatic ductal adenocarcinoma are associated with worse outcomes compared to KRAS wild-type. KRAS G12R mutation is linked to more favorable patient outcomes, with ...

This regimen appears to be both effective and well-tolerated, especially for patients with wild-type KRAS mCRC who had previously responded to treatment. Colorectal cancer is one of the leading ...

Verastem's assets, Avutometinib and Defactinib, show promising results in treating KRAS-mutated LGSOC. Read why VSTM stock is a Hold.

FDA-approved drugs sotorasib and adagrasib have given new hope to some patients by targeting this KRAS G12C mutation ... FGTI-2734 blocks cancer cells' wild type RAS membrane localization ...

FDA-approved drugs sotorasib and adagrasib have given new hope to some patients by targeting this KRAS G12C mutation ... FGTI-2734 blocks cancer cells’ wild type RAS membrane localization ...

RICHMOND - A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib—an FDA ...